EGFR and non-small cell lung carcinoma: However, co-existing EGFR-mutations and ALK-rearrangements have been reported in a small but relevant number of NSCLC patients (reportedly from 0.09% to 1.6% of all NSCLs) and a prevalence ranging from 0.5% to 4% of EGFRM+ NSCLCs and from 4.4% to 19% of ALK-rearranged NSCLCs (highest in East Asian patients), depending on the study and utilized detection methods [3,42,45,125,126,127,128].